CN107635566A - 治疗hbv感染的组合物和方法 - Google Patents

治疗hbv感染的组合物和方法 Download PDF

Info

Publication number
CN107635566A
CN107635566A CN201680033034.8A CN201680033034A CN107635566A CN 107635566 A CN107635566 A CN 107635566A CN 201680033034 A CN201680033034 A CN 201680033034A CN 107635566 A CN107635566 A CN 107635566A
Authority
CN
China
Prior art keywords
formula
compound
subject
less
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680033034.8A
Other languages
English (en)
Chinese (zh)
Inventor
R.P.伊耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Star Therapeutics Inc
Original Assignee
Spring Bank Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals Inc filed Critical Spring Bank Pharmaceuticals Inc
Publication of CN107635566A publication Critical patent/CN107635566A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201680033034.8A 2015-04-07 2016-04-07 治疗hbv感染的组合物和方法 Pending CN107635566A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562144300P 2015-04-07 2015-04-07
US62/144,300 2015-04-07
US201562220406P 2015-09-18 2015-09-18
US62/220,406 2015-09-18
US201662279382P 2016-01-15 2016-01-15
US62/279,382 2016-01-15
PCT/US2016/026498 WO2016164619A2 (en) 2015-04-07 2016-04-07 Compositions and methods for the treatment of hbv infection

Publications (1)

Publication Number Publication Date
CN107635566A true CN107635566A (zh) 2018-01-26

Family

ID=57072854

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680033034.8A Pending CN107635566A (zh) 2015-04-07 2016-04-07 治疗hbv感染的组合物和方法

Country Status (10)

Country Link
US (1) US20180110796A1 (enExample)
EP (1) EP3280422A4 (enExample)
JP (1) JP2018512428A (enExample)
KR (1) KR20170132327A (enExample)
CN (1) CN107635566A (enExample)
AU (1) AU2016244828A1 (enExample)
CA (1) CA2982125A1 (enExample)
HK (1) HK1250480A1 (enExample)
TW (1) TW201709912A (enExample)
WO (1) WO2016164619A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116568309A (zh) * 2020-11-18 2023-08-08 株式会社车疫苗研究所 用于预防或治疗慢性乙型肝炎的、包含作为活性成分的口服抗病毒药物和含脂肽和聚(i：c)佐剂的治疗性疫苗的药物组合物、药物组合制剂和组合制剂试剂盒

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290673A1 (en) * 2016-10-24 2019-09-26 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hbv infection
KR101899773B1 (ko) * 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
WO2020040327A1 (ko) * 2018-08-23 2020-02-27 광주과학기술원 시클로피록스의 hbv 코어조립 저해 용도
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CA3155068A1 (en) * 2019-09-29 2021-04-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination containing tlr7 agonist
EP4037706A4 (en) * 2019-10-02 2023-09-13 University of Washington Compositions and methods for treatment of hepatitis b virus infection
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
WO2022115765A1 (en) * 2020-11-30 2022-06-02 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis e virus infection with interferon lambda

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030329A2 (en) * 1999-10-29 2001-05-03 Glaxo Group Limited Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
US20030158149A1 (en) * 2000-03-29 2003-08-21 Casey John L. Method of treating hepatitis delta virus infection
CN101278938A (zh) * 2008-03-20 2008-10-08 黑龙江加州国际投资咨询有限公司 泰诺福韦酯和恩替卡韦的复方制剂及其抗乙肝病毒的应用
CN103298475A (zh) * 2010-08-30 2013-09-11 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2913889A (en) * 1987-11-16 1989-06-14 Fox Chase Cancer Center Determination of anti-pol as an early marker of viral hepatitis infection
US7202354B2 (en) * 2001-03-30 2007-04-10 Abbott Laboratories Hepatitis B virus surface antigen mutant and methods of detection thereof
CA2529997A1 (en) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Novel surface protein (hbsag) variant of hepatitis b virus
EP2271351A4 (en) * 2008-04-03 2016-08-31 Spring Bank Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030329A2 (en) * 1999-10-29 2001-05-03 Glaxo Group Limited Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
US20030158149A1 (en) * 2000-03-29 2003-08-21 Casey John L. Method of treating hepatitis delta virus infection
CN101278938A (zh) * 2008-03-20 2008-10-08 黑龙江加州国际投资咨询有限公司 泰诺福韦酯和恩替卡韦的复方制剂及其抗乙肝病毒的应用
CN103298475A (zh) * 2010-08-30 2013-09-11 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
胡仕琦 等编著: "《肝病知识与咨询热点（第2版）》", 30 June 2011, 科学技术文献出版社 *
陈万青 等主编: "《常见消化系统恶性肿瘤预防和控制》", 30 November 2014, 军事医学科学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116568309A (zh) * 2020-11-18 2023-08-08 株式会社车疫苗研究所 用于预防或治疗慢性乙型肝炎的、包含作为活性成分的口服抗病毒药物和含脂肽和聚(i：c)佐剂的治疗性疫苗的药物组合物、药物组合制剂和组合制剂试剂盒

Also Published As

Publication number Publication date
AU2016244828A1 (en) 2017-10-26
EP3280422A2 (en) 2018-02-14
WO2016164619A3 (en) 2016-12-08
WO2016164619A2 (en) 2016-10-13
EP3280422A4 (en) 2018-12-05
JP2018512428A (ja) 2018-05-17
HK1250480A1 (zh) 2018-12-21
US20180110796A1 (en) 2018-04-26
KR20170132327A (ko) 2017-12-01
TW201709912A (zh) 2017-03-16
CA2982125A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CN107635566A (zh) 治疗hbv感染的组合物和方法
KR102181168B1 (ko) Hbv 캡시드 조립 억제제와 인터페론의 조합 치료
JP6922030B2 (ja) Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法
TW201717968A (zh) 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
WO2018087345A1 (en) COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
ES3008560T3 (en) Treatment of hepatitis delta virus infection with interferon lambda
US20180185404A1 (en) Compositions and methods for the treatment of viral infection
CN118845776A (zh) 治疗丁型肝炎病毒感染
JP2022167901A (ja) パラポックスウイルス・オヴィス（Ｐａｒａｐｏｘｖｉｒｕｓ ｏｖｉｓ：ＰＰＶＯ）、および少なくとも一つの追加の抗ウイルス薬を使用したＢ型肝炎ウイルス（ＨＢＶ）感染者の併用療法
EP2776024A1 (en) Methods and compositions for treating hepatitis c virus
US20190070212A1 (en) Compounds and compositions for the treatment of infections
KR20220018552A (ko) 항 간염 바이러스 의약품 제조를 위한 암렉사녹스의 용도
JPH05507481A (ja) ウイルス性肝炎の診断及び治療
US20190290673A1 (en) Compositions and methods for the treatment of hbv infection
WO2022213870A1 (zh) 通过口服给药抑制CD4+Treg细胞的药物和方法
EP2305234A1 (en) Pharmaceutical composition for treatment or prevention of hbv infection
US20190046552A1 (en) Compositions and methods for the treatment of hcv infection
US20220257540A1 (en) Compositions and methods for treatment of hepatitis b virus infection
WO2021092554A1 (en) Pharmaceutical compositions and methods for treating hbv disorders
WO2010044474A1 (ja) Ｃ型肝炎治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180126

WD01 Invention patent application deemed withdrawn after publication